Galderma, renowned for its leadership in dermatology, and L’Oréal, a giant in beauty and skincare, have unveiled a groundbreaking partnership marked by L’Oréal acquiring a 10% stake in Galderma. This alliance is poised to reshape the dermatological landscape, combining Galderma’s scientific prowess in skin health with L’Oréal’s expertise in beauty innovations. Unleashing Innovation in Dermatology […]
Motorola Solutions (NYSE: MSI) has announced the opening of a new Research and Development Centre in Cork, Ireland, a strategic move expected to create 200 highly skilled jobs. This new facility will focus on developing software for the company’s extensive land mobile radio (LMR) portfolio, with potential future expansion into other technological areas. Motorola Solutions’ […]
Bharat Electronics Limited (BEL), a leading Navratna Defence Public Sector Undertaking, has announced a remarkable performance for the financial year 2023-24, with a turnover of approximately Rs. 19,700 crore (provisional and unaudited). This achievement marks a significant growth of 13.65% over the previous year’s turnover of Rs. 17,333 crore, demonstrating the company’s sustained growth trajectory […]
Siemens Mobility is setting a remarkable precedent in the rail industry with a hefty €115 million investment to establish a state-of-the-art rail infrastructure manufacturing, digital engineering, and research & development (R&D) center in Chippenham, UK. This development is not just a testament to the company’s dedication to innovation, sustainability, and excellence but also marks a […]
Bajaj Healthcare Ltd., a prominent figure in the pharmaceutical industry specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), Intermediates, and Formulations, has announced a significant development. The company has entered into a definitive Contract Development and Manufacturing Organization (CDMO) agreement with esteemed customers based in the UK and EU for the supply of 15 […]
X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases and cancer. This strategic move unites two Massachusetts-based companies, with X4 Pharmaceuticals specializing in immune cell trafficking therapies for conditions such as primary immunodeficiencies and cancer, and Arsanis leading the charge in monoclonal antibody (mAb) immunotherapies for […]